The 2023 edition of the American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium will take place from February 16 to February 18, 2023 in Moscone West, San Francisco. ASCO-GU 2023 showcases ground-breaking research regarding the diagnosis and treatment of GU malignancies. Over the course of the three conference days, 800+ abstracts will be presented in a hybrid format, using both in-person and online sessions.

Most Highly Anticipated Abstracts

ASCO-GU has released the abstract titles as of January 10th. Below are some of the most highly anticipated abstracts among healthcare professionals.

  • Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

PROpel, NCT03732820 | AstraZeneca (Abiraterone, Olaparib)

Session Type: General Session

Indication: First-Line Metastatic Castration-Resistant Prostate Cancer

Author: Noel Clarke

  • Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.

KEYNOTE 921, NCT03834506, | Merck (Docetaxel, Pembrolizumab)

Session Type: Poster Session

Indication: Metastatic Castration-Resistant Prostate Cancer
Author: Daniel Petrylak

  • Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

CheckMate 9ER, NCT03141177 | Bristol-Myers Squibb (Cabozantinib, Nivolumab)

Session Type: Oral Session

Indication: First-Line Advanced Renal Cell Carcinoma

Author: Mauricio Burotto

  • Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.

TRITON3, NCT02975934 | Clovis Oncology (Rucaparib)

Session Type: Oral Session

Indication: Metastatic Castration-Resistant Prostate Cancer

Author: Alan Bryce

  • Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.

JAVELIN Bladder 100, NCT02603432 | Pfizer (Avelumab)

Session Type: Poster Session

Indication: First-Line Advanced Urothelial Carcinoma
Author: Srikala Sridhar

Drugs in Focus: Additional High-Profile Abstracts

Here are a few additional abstracts of interest for significant FDA-approved medications.

Cabozantinib in combination with Nivolumab

  • Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

CheckMate 9ER, NCT03141177 | Bristol-Myers Squibb

Session Type: Oral Session

Indication: First-Line Advanced Renal Cell Carcinoma

Author: Mauricio Burotto

  • CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.

CaboCombo, NCT05361434 | Ipsen

Session Type: Poster Session

Indication: Advanced Renal Cell Carcinoma

Author: Philippe Barthelemy

  • Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).

CheckMate 9ER, NCT03141177 | Bristol-Myers Squibb

Session Type: Rapid Abstract Session

Indication: Advanced Renal Cell Carcinoma

Author: Toni Choueiri

Avelumab

  • Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.

JAVELIN Bladder 100, NCT02603432 | Pfizer

Session Type: Poster Session

Indication: First-Line Advanced Urothelial Carcinoma
Author: Srikala Sridhar

  • Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).

AVENANCE, NCT04822350 | Merck and Pfizer

Session Type: Poster Session

Indication: First-line Advanced Urothelial Carcinoma

Author: Philippe Barthelemy

  • Activity and tolerability of maintenance avelumab (AVE) immunotherapy after first-line platinum-based polychemotherapy in patients (pts) with locally advanced or metastatic squamous cell penile carcinoma: Initial results of PULSE study.

PULSE, NCT03774901 | Pfizer

Session Type: Poster Session

Indication : Locally Advanced or Metastatic Squamous Cell Penile Carcinoma

Author: Antoine Thiery-Vuillemin

Gemcitabine, Cisplatin plus Nivolumab

  • Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).

HCRN GU 16-257, NCT03558087 | Bristol-Myers Squibb

Session Type: Poster Session

Indication : Muscle Invasive Bladder Cancer

Author: Matt Galsky

  • Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.

BLASST-1, NCT03294304 | Veracyte

Session Type: Poster Session

Indication : Muscle Invasive Bladder Cancer

Author: Shilpa Gupta

A more comprehensive overview will be published once the abstracts are released.

ZoomRx uses the info you provide to fulfill your request and contact you about relevant insights, products, and services. You may unsubscribe from all communications at any time. For more information, view our full privacy policy